SCHEMBL2998623

SCHEMBL2998623

Cc1ccc(C)c(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
EPHX2 P34913 2/20 0.35
TSHR P16473 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
AR P10275 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 2/20 0.34
ALDH3A1 P30838 1/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RECQL P46063 1/20 0.34
DNM1L O00429 2/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3010811 0.93 EPHX2 (0.37) MAPTLMNATP53EPHX2AR
SCHEMBL3003909 0.91 CTSS (0.40) MAPTLMNATP53EPHX2AR
SCHEMBL3017318 0.91 MAPT (0.35) MAPTLMNATP53EPHX2NPSR1
SCHEMBL3014184 0.90 RECQL (0.38) MAPTLMNATSHRNPSR1HTT
SCHEMBL3016068 0.90 MAPK1 (0.38) MAPTLMNATP53TSHRHTT
SCHEMBL3011591 0.89 ACHE (0.36) MAPTLMNATP53TSHRNPSR1
SCHEMBL3015699 0.88 EPHX2 (0.35) MAPTEPHX2TSHRNPSR1HTT
SCHEMBL3013654 0.88 DRD2 (0.39) MAPTLMNATP53EPHX2TSHR
SCHEMBL3014116 0.88 MAPT (0.44) MAPTLMNATP53TSHRNPSR1
SCHEMBL3007243 0.88 MAPT (0.36) MAPTLMNATP53TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.